The selection of RetroSense as one MIT Technology Review’s 50 Smartest Companies in 2016 highlights the technological significance of RetroSense’s novel therapy.
Clinical trial to assess the safety and, potentially efficacy, of novel gene therapy application of optogenetics in patients with retinitis pigmentosa
At the Venture Awards Russia 2015 ceremony, December 5, Russia’s first VC award went to RBV Capital in the New Player of the Year nomination.
RetroSense Therapeutics Raises $6 million in an Over-Subscribed Series B Financing to Advance Clinical Development of Lead Product RST‐001 for Retinitis Pigmentosa
Patient recruitment underway for Phase I/II clinical study RetroSense Therapeutics, a privately‐held, clinical-stage biopharmaceutical company, today announced that it has secured $6 million in a Series B financing to further investigate the use of gene therapy and optogenetics to restore vision.
The managing company of RBV Capital has an open position for an investment analyst/manager. Background/education in medicine, biotech or life sciences, investment experience in pharma/healthcare, work experience in pharma companies or other relevant experience very welcome.